Followers | 261 |
Posts | 19732 |
Boards Moderated | 0 |
Alias Born | 10/03/2004 |
![](https://investorshub.advfn.com/uicon/45965.png?cb=1637315758)
Wednesday, August 17, 2016 6:15:56 PM
Arms Assigned Interventions
Experimental: AC5 Treatment on Wound
Treatment of skin lesion with topical hemostatic (AC5)
Device: Application of AC5 Hemostatic agent
Application of the hemostatic agent will be applied to the skin lesion directly as prescribed
Active Comparator: Standard Treatment of Wound
Treatment of skin lesion with water resistant dressing
Device: Standard application of water resistant dressing
Application of a water resistant dressing to the skin lesion as prescribed
https://clinicaltrials.gov/ct2/show/NCT02704104?term=AC5+arch&rank=1
The current standard of care is aluminum chloride topical dressing for both malignant and nonmalignant tumor removal (neoplasmic excision). Average time to hemostasis is about 80 seconds. A 41% reduction would be 47 seconds.
These are from online sources, so if anyone knows better or especially anyone with experience in this area, please feel free to correct or further detail the above.
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM